openPR Logo
Press release

AstraZeneca VP of Biological Reagents & Assay Development joins speaker lineup for Drug Discovery 2017

02-07-2017 05:58 PM CET | Health & Medicine

Press release from: SMi Group

AstraZeneca VP of Biological Reagents & Assay Development joins

Lorenz Mayr, esteemed Vice President and Global Head of Biological Reagents and Assay Development at AstraZeneca will be joining the expert speaker lineup for the launch conference on Drug Discovery. The event takes place on the 27th and 28th of April 2017 in London.

With a focus on CRISPR/Cas9 technology, Lorenz's keynote address will explore how this new emerging technique has become a pivotal new approach for drug discovery, particularly in target discovery, hit finding and translational studies. A few key points include:

an overview of PGE and introduction to CRISPR/Cas9 technology
applications in target finding, hit and lead discovery, efficacy and safety models
AstraZeneca's unique approach towards innovation and collaboration
case studies from AstraZeneca's drug discovery programmes
future outlook of PGE for drug discovery and therapeutic applications.
Lorenz will be speaking on Day 1 of the conference and joins lead decision-makers and industry innovators from Sanofi, Takeda, Merck Serono, AbbVie, GSK, Johnson & Johnson, UCB Pharma, Eli Lilly and more. A full list of speakers can be found on www.drug-discovery.co.uk/OpenPR.

SMi's Drug Discovery conference aims to bridge the gaps in approval for drug discovery and development by discussing the latest scientific breakthroughs, exploring novel technologies and approaches that can be used to overcome drug development challenges.

The event will also feature two post-conference workshops on new approaches in lead generation and applications of physicochemical and biomimetic properties in early drug discovery.

For more details about the conference and to register, visit www.drug-discovery.co.uk/OpenPR.

Drug Discovery
27-28 March 2017
Holiday Inn Kensington Forum, London, UK
www.drug-discovery.co.uk/openpr

---end ---

Contact Information:
For sponsorship and exhibition queries please contact Alia Malick at amalick@smi-online.co.uk. For delegate queries please contact Fateja Begum at fbegum@smi-online.co.uk. For media queries please contact Honey de Gracia at hdegracia@smi-online.co.uk.

About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

1 Westminster Bridge Road, London, SE1 7XW

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release AstraZeneca VP of Biological Reagents & Assay Development joins speaker lineup for Drug Discovery 2017 here

News-ID: 430799 • Views:

More Releases from SMi Group

Exclusive Speaker Interview with AOBiome ahead of the 22nd Pain Therapeutics Conference
Exclusive Speaker Interview with AOBiome ahead of the 22nd Pain Therapeutics Con …
SMi Reports: Exclusive speaker interview with Todd Krueger at AOBiome released for the Pain Therapeutics Conference The pain therapeutics industry has grown at an exponential rate in recent years. The 22nd Annual Pain Therapeutics conference will cover the leading advances in pain therapeutics, exploring late development clinical trials, novel treatments for chronic conditions, technology collaboration treatments, using VR and Medical Devices that carry out non-invasive nerve stimulation. Industry leaders will uncover the
Exclusive Speaker Interview with Ester Lovsin Barle ahead of the 6th Annual Highly Potent Active Pharmaceutical Ingredients Conference.
Exclusive Speaker Interview with Ester Lovsin Barle ahead of the 6th Annual High …
Now in its 6th year, the Highly Potent Active Pharmaceutical Ingredients conference offers you peer-to-peer networking with industry experts including heads and directors of EHS, Occupational Hygiene, Quality Assurance and more. Taking place on 9th and 10th May in London, UK. With a key focus on expanding your community and exploring the latest developments in the industry at this two-day event, including key regulatory updates, and leading case studies from leading
FDA Keynote Speaker at SMi's 5th Annual Pharmaceutical Microbiology East Coast Conference in Boston, USA
FDA Keynote Speaker at SMi's 5th Annual Pharmaceutical Microbiology East Coast C …
SMi Group Reports: Keynote FDA speaker Dr. John Arigo, to present at the 4th Annual Pharmaceutical Microbiology East Coast, taking place in just 3 weeks' time on April 27th and 28th, 2022. With just three weeks remaining until the highly anticipated conference, SMi Group are delighted to announce a key FDA Speaker joining the 5th Annual Pharmaceutical Microbiology East Coast Conference. This event will take place on April 27th and
Group Captain (ret'd) Robert Daisley invites you to attend Air Mission Planning …
SMi Group reports: Chairman Group Captain (ret'd) Robert Daisley of the Air Mission Planning and Support Conference cordially invites experts to join the conference in London, UK in one week. With only one week remaining, SMi Group is delighted to publish an invitation letter for SMi's 13th Annual Air Mission Planning & Support Conference, taking place on the 6th and 7th April 2022 in London, UK from the conference chairman. The

All 5 Releases


More Releases for AstraZeneca

Hypereosinophilic Syndrome Market Revenue to Expand Significantly by 2032, State …
The Key Hypereosinophilic Syndrome Companies in the market include - GlaxoSmithKline, AstraZeneca, Novartis, M.D. Anderson Cancer Center, AstraZeneca, and others. DelveInsight's "Hypereosinophilic Syndrome Market Insights, Epidemiology, and Market Forecast-2032 report offers an in-depth understanding of the Hypereosinophilic Syndrome, historical and forecasted epidemiology as well as the Hypereosinophilic Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. The latest healthcare forecast report provides an in-depth
DNA Repair Drugs Market May See a Big Move | Major Giants- AbbVie, AstraZeneca, …
The latest study released on the Global DNA Repair Drugs Market by HTF MI evaluates market size, trend, and forecast to 2030. The DNA Repair Drugs market study covers significant research data and proofs to be a handy resource document for managers, analysts, industry experts and other key people to have ready-to-access and self-analyzed study to help understand market trends, growth drivers, opportunities and upcoming challenges and about the competitors. Key
Calcium Channel Antagonist Market Will Reflect Significant Growth Prospects By 2 …
The Calcium Channel Antagonist report compiles the market information depending upon market development and growth factors, optimizing the growth path. In addition, it highlights the strategies and market share of the leading vendors in the particular market. The report follows a robust research methodology model that helps to make informed decisions. It obtains both qualitative and quantitative market information supported by primary research. Download FREE Sample Report @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=7764202 The Calcium
Nasal Polyposis Market to Witness Growth by (2022-2032), Estimates DelveInsight …
The Nasal Polyposis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Nasal Polyposis pipeline products will significantly revolutionize the Nasal Polyposis market dynamics. DelveInsight's "Nasal Polyposis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Nasal Polyposis, historical and forecasted epidemiology as well as the Nasal Polyposis market trends in the
Global Influenza Vaccines Market: Emerging Trends, Major Key Players Astrazeneca …
According to the report, The global Influenza Vaccines market is expected to grow from $ billion in 2020 to $ billion in 2028 at a CAGR of 15%. Request Free Sample Report or PDF Copy: https://report.evolvebi.com/index.php/sample/request?referer=OpenPR&reportCode=006954 The latest research report published by Evolve Business Intelligence examines the impacts of numerous market aspects on the global INFLUENZA VACCINES industry including a look at the current market size and forecasts for key segments and
What's driving the Cannula Market Growth? Prominent Players Merck, AstraZeneca, …
The global cannula market is estimated to grow to USD 222.09 million by 2026 growing at a substantial CAGR during the forecast period of 2019 to 2026. The rise in market value can be factored to the growing preference of minimally invasive surgical procedures from the patients.Global Cannula Market By Product (Vascular Cannula, Cardiac Cannula, Arthroscopy Cannula, Dermatology Cannula, Nasal Cannula, Others), Type (Neonatal, Straight, Winged, Wing with Port, Winged